FDA authorized molecular point-of-care SARS-CoV-2 tests: A critical review on principles, systems and clinical performances

[1]  A. Peretz,et al.  Rapid SARS-CoV-2 Detection Using the Lucira™ Check It COVID-19 Test Kit , 2022, Diagnostics.

[2]  Vincent Deslandes,et al.  Implementation of the Abbott ID Now COVID-19 assay at a tertiary care center: a prospective pragmatic implementation study during the third wave of SARS-CoV-2 in Ontario , 2021, Diagnostic Microbiology and Infectious Disease.

[3]  L. Donato,et al.  Evaluation of the Visby medical COVID-19 point of care nucleic acid amplification test , 2021, Clinical Biochemistry.

[4]  S. Mitchell,et al.  Performance of SARS-CoV-2 antigen testing in symptomatic and asymptomatic adults: a single-center evaluation , 2021, BMC Infectious Diseases.

[5]  Monia Chemais,et al.  A brief performance evaluation and literature review of Abbott ID Now COVID-19 rapid molecular-based test , 2021, Journal of Virological Methods.

[6]  M. Krause,et al.  Molecular point-of-care testing for SARS-CoV-2 using the ID NOW(TM) System in Emergency Department: Prospective Evaluation and Implementation in the Care Process , 2021, medRxiv.

[7]  S. Perera,et al.  Molecular diagnostics in the era of COVID-19. , 2021, Analytical methods : advancing methods and applications.

[8]  H. Rennert,et al.  Performance Evaluation of the MatMaCorp COVID-19 2SF Assay for the Detection of SARS-CoV-2 from Nasopharyngeal Swabs , 2021, Microbiology spectrum.

[9]  Ji-Rong Yang,et al.  Clinical Comparison of Three Sample-to-Answer Systems for Detecting SARS-CoV-2 in B.1.1.7 Lineage Emergence , 2021, Infection and drug resistance.

[10]  M. Oethinger,et al.  Performance Characteristics of the Roche Diagnostics cobas Liat PCR System as a COVID-19 Screening Tool for Hospital Admissions in a Regional Health Care Delivery System , 2021, Journal of clinical microbiology.

[11]  M. Loeffelholz,et al.  Detection of SARS-CoV-2 at the point of care , 2021, Bioanalysis.

[12]  G. Fischer,et al.  Rapid and Safe Detection of SARS-CoV-2 and Influenza Virus RNA using Onsite qPCR Diagnostic Testing from Clinical Specimens Collected in Molecular Transport Medium , 2021, The journal of applied laboratory medicine.

[13]  T. S. Chow,et al.  Excellent negative predictive value (99.8%) of two rapid molecular COVID-19 tests compared to conventional RT-PCR for SARS-CoV-2 (COVID-19) in 2,011 tests performed in a single centre. , 2021, medRxiv.

[14]  G. Soraya,et al.  The diagnostic accuracy of seven commercial molecular in vitro SARS-CoV-2 detection tests: a rapid meta-analysis , 2021, Expert review of molecular diagnostics.

[15]  S. Ganesan,et al.  Evaluation of six different rapid methods for nucleic acid detection of SARS‐COV‐2 virus , 2021, Journal of medical virology.

[16]  P. Granato,et al.  Comparative evaluation of the Thermo fisher TaqPath™ COVID-19 combo kit with the Cepheid Xpert® Xpress SARS-CoV-2 assay for detecting SARS-CoV-2 in nasopharyngeal specimens , 2021, BMC Infectious Diseases.

[17]  Jonghoo Lee,et al.  Diagnostic accuracy of the Cepheid Xpert Xpress and the Abbott ID NOW assay for rapid detection of SARS‐CoV‐2: A systematic review and meta‐analysis , 2021, Journal of medical virology.

[18]  S. Yerly,et al.  Analytical Evaluation of Visby Medical RT-PCR Portable Device for Rapid Detection of SARS-CoV-2 , 2021, Diagnostics.

[19]  W. Cho,et al.  Performance comparison of the Cobas® Liat® and Cepheid® GeneXpert® systems on SARS-CoV-2 detection in nasopharyngeal swab and posterior oropharyngeal saliva , 2021, Expert review of molecular diagnostics.

[20]  T. O'Leary,et al.  Sensitivity of ID NOW and RT–PCR for detection of SARS-CoV-2 in an ambulatory population , 2021, eLife.

[21]  S. Ganesan,et al.  Evaluation of seven different rapid methods for nucleic acid detection of SARS-COV-2 virus , 2021, medRxiv.

[22]  V. Enouf,et al.  Prospective evaluation of ID NOW COVID-19 assay used as point-of-care test in an emergency department , 2021, Journal of Clinical Virology.

[23]  J. Reppas,et al.  Pooling in a Pod: A Strategy for COVID-19 Testing to Facilitate a Safe Return to School , 2021, medRxiv.

[24]  L. Hooft,et al.  Rapid, point‐of‐care antigen tests for diagnosis of SARS‐CoV‐2 infection , 2021, The Cochrane database of systematic reviews.

[25]  Wei-Kung Wang,et al.  Validation of the GeneXpert Xpress SARS-CoV-2 PCR assay using saliva as biological specimen , 2021, The Brazilian Journal of Infectious Diseases.

[26]  B. Pritt,et al.  Evaluation of the Cue Health point-of-care COVID-19 (SARS-CoV-2 nucleic acid amplification) test at a community drive through collection center , 2021, Diagnostic Microbiology and Infectious Disease.

[27]  Kok-Gan Chan,et al.  Nucleic Acid-Based Diagnostic Tests for the Detection SARS-CoV-2: An Update , 2021, Diagnostics.

[28]  P. Granato,et al.  Comparative Evaluation of the Thermo Fisher TaqPath TM COVID-19 Combo Kit with the Cepheid Xpert ® Xpress SARS-CoV-2 Assay for Detecting SARS-CoV-2 in Nasopharyngeal Specimens , 2021 .

[29]  K. Pabbaraju,et al.  Acceptable performance of the Abbott ID NOW among symptomatic individuals with confirmed COVID-19 , 2020, medRxiv.

[30]  L. Westblade,et al.  Clinical Performance of the Point-of-Care cobas Liat for Detection of SARS-CoV-2 in 20 Minutes: a Multicenter Study , 2020, Journal of Clinical Microbiology.

[31]  G. Procop,et al.  A Comparison of Five SARS-CoV-2 Molecular Assays With Clinical Correlations , 2020, American journal of clinical pathology.

[32]  T. Kirn,et al.  Comparison of abbott ID NOW COVID-19 rapid molecular assay to cepheid xpert xpress SARS-CoV-2 assay in dry nasal swabs , 2020, Diagnostic Microbiology and Infectious Disease.

[33]  P. V. Van Caeseele,et al.  Comparison of commercial assays and laboratory developed tests for detection of SARS-CoV-2 , 2020, Journal of Virological Methods.

[34]  L. Schroeder,et al.  Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performance is impaired substantially by patient and specimen type☆ , 2020, Diagnostic Microbiology and Infectious Disease.

[35]  H. Frickmann,et al.  Evaluation of the automated cartridge-based ARIES SARS-CoV-2 Assay (RUO) against automated Cepheid Xpert Xpress SARS-CoV-2 PCR as gold standard , 2020, European journal of microbiology & immunology.

[36]  R. Lai,et al.  Evaluation on testing of deep throat saliva and lower respiratory tract specimens with Xpert Xpress SARS-CoV-2 assay , 2020, Journal of Clinical Virology.

[37]  J. Zehnder,et al.  Comparison of a Point-of-Care Assay and a High-Complexity Assay for Detection of SARS-CoV-2 RNA , 2020, The journal of applied laboratory medicine.

[38]  Shan X. Wang,et al.  Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape , 2020, Biosensors and Bioelectronics.

[39]  A. Deucher,et al.  Direct Comparison of SARS-CoV-2 Analytical Limits of Detection across Seven Molecular Assays , 2020, Journal of Clinical Microbiology.

[40]  M. Pettengill,et al.  Commercial SARS-CoV-2 Molecular Assays: Superior Analytical Sensitivity of cobas SARS-CoV-2 Relative to NxTAG Cov Extended Panel and ID NOW COVID-19 Test. , 2020, Archives of pathology & laboratory medicine.

[41]  H. Hirsch,et al.  Brief validation of the novel GeneXpert Xpress SARS-CoV-2 PCR assay , 2020, Journal of Virological Methods.

[42]  H. Jarva,et al.  SARS-CoV-2 sample-to-answer nucleic acid testing in a tertiary care emergency department: evaluation and utility , 2020, Journal of Clinical Virology.

[43]  P. M. Thwe,et al.  How many are we missing with ID NOW COVID-19 assay using direct nasopharyngeal swabs? Findings from a mid-sized academic hospital clinical microbiology laboratory , 2020, Diagnostic Microbiology and Infectious Disease.

[44]  H. Hou,et al.  Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Assay for the Detection of SARS-CoV-2 in Oropharyngeal Swab Specimens , 2020, Journal of Clinical Microbiology.

[45]  S. Foster,et al.  Performance characteristics of the ID NOW COVID-19 assay: A regional health care system experience , 2020, medRxiv.

[46]  A. E. Clark,et al.  Evaluation of symptomatic patient saliva as a sample type for the Abbott ID NOW COVID-19 assay , 2020, medRxiv.

[47]  Atreyee Basu,et al.  Performance of Abbott ID Now COVID-19 Rapid Nucleic Acid Amplification Test Using Nasopharyngeal Swabs Transported in Viral Transport Media and Dry Nasal Swabs in a New York City Academic Institution , 2020, Journal of Clinical Microbiology.

[48]  Kendall W. Cradic,et al.  Clinical Evaluation and Utilization of Multiple Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2 , 2020, American journal of clinical pathology.

[49]  M. Hayden,et al.  Comparison of Two Commercial Molecular Tests and a Laboratory-Developed Modification of the CDC 2019-nCoV Reverse Transcriptase PCR Assay for the Detection of SARS-CoV-2 , 2020, Journal of Clinical Microbiology.

[50]  Stephanie L. Mitchell,et al.  Evaluation of the COVID19 ID NOW EUA assay , 2020, Journal of Clinical Virology.

[51]  J. Zehnder,et al.  Comparison of the Accula SARS-CoV-2 Test with a Laboratory-Developed Assay for Detection of SARS-CoV-2 RNA in Clinical Nasopharyngeal Specimens , 2020, Journal of Clinical Microbiology.

[52]  E. Burd,et al.  Test Agreement between Roche Cobas 6800 and Cepheid GeneXpert Xpress SARS-CoV-2 Assays at High Cycle Threshold Ranges , 2020, Journal of Clinical Microbiology.

[53]  J. Kop,et al.  Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Test , 2020, Journal of Clinical Microbiology.

[54]  Meei-Li W Huang,et al.  Comparison of Commercially Available and Laboratory-Developed Assays for In Vitro Detection of SARS-CoV-2 in Clinical Laboratories , 2020, Journal of Clinical Microbiology.

[55]  M. Smithgall,et al.  Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2 , 2020, bioRxiv.

[56]  Deborah Schron,et al.  Clinical Evaluation of Three Sample-to-Answer Platforms for Detection of SARS-CoV-2 , 2020, Journal of Clinical Microbiology.

[57]  A. Harrington,et al.  Comparison of Abbott ID Now and Abbott m2000 Methods for the Detection of SARS-CoV-2 from Nasopharyngeal and Nasal Swabs from Symptomatic Patients , 2020, Journal of Clinical Microbiology.

[58]  K. Beavis,et al.  Detection of SARS-CoV-2 by Use of the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas SARS-CoV-2 Assays , 2020, Journal of Clinical Microbiology.

[59]  C. Schmotzer,et al.  Comparison of Abbott ID Now, DiaSorin Simplexa, and CDC FDA Emergency Use Authorization Methods for the Detection of SARS-CoV-2 from Nasopharyngeal and Nasal Swabs from Individuals Diagnosed with COVID-19 , 2020, Journal of Clinical Microbiology.

[60]  M. Slaughter.  COVID-19 Update , 2020, ASAIO journal.

[61]  L Rampal,et al.  Coronavirus disease (COVID-19) pandemic. , 2020, The Medical journal of Malaysia.

[62]  Hongzhou Lu,et al.  Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle , 2020, Journal of medical virology.

[63]  Jian Wu,et al.  Technical aspects of nicking enzyme assisted amplification. , 2018, The Analyst.

[64]  E. Petricoin,et al.  Molecular Diagnostics , 2023, Springer Singapore.

[65]  K. L. Meier.  Reporting results from studies evaluating diagnostic tests , 2002 .

[66]  A Hornsleth,et al.  [Clinical virology]. , 1977, Ugeskrift for laeger.